Markus Warmuth

18.8k total citations
48 papers, 3.1k citations indexed

About

Markus Warmuth is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Markus Warmuth has authored 48 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 23 papers in Molecular Biology and 16 papers in Genetics. Recurrent topics in Markus Warmuth's work include Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cancer-related Molecular Pathways (6 papers). Markus Warmuth is often cited by papers focused on Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Cancer-related Molecular Pathways (6 papers). Markus Warmuth collaborates with scholars based in United States, Germany and Switzerland. Markus Warmuth's co-authors include Michael Hallek, Katja Zirlik, Hendrik Veelken, Christine Dierks, Doriano Fabbro, S. Danhauser-Riedl, Gang Xia, Marion Dorsch, Paul W. Manley and Nathanael S. Gray and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Markus Warmuth

45 papers receiving 3.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Markus Warmuth 1.7k 1.2k 930 885 412 48 3.1k
Christopher A. Eide 1.6k 0.9× 2.3k 1.9× 802 0.9× 1.6k 1.8× 270 0.7× 97 3.9k
Juerg Schwaller 2.1k 1.2× 1.3k 1.1× 1.2k 1.3× 569 0.6× 844 2.0× 66 3.8k
Raajit K. Rampal 1.7k 1.0× 1.6k 1.3× 495 0.5× 1.6k 1.9× 244 0.6× 178 3.3k
David R. Stover 1.4k 0.8× 960 0.8× 1.1k 1.2× 408 0.5× 139 0.3× 47 3.0k
Marc Loriaux 2.0k 1.2× 2.2k 1.8× 808 0.9× 2.1k 2.4× 510 1.2× 98 4.5k
Shu Tamura 1.0k 0.6× 2.5k 2.1× 713 0.8× 1.6k 1.8× 259 0.6× 11 3.7k
Ilaria Iacobucci 1.1k 0.6× 2.4k 2.0× 587 0.6× 1.5k 1.7× 269 0.7× 165 3.7k
Hans D. Menssen 772 0.5× 2.0k 1.6× 1.0k 1.1× 1.5k 1.7× 230 0.6× 64 3.5k
Thomas Mercher 2.4k 1.4× 2.0k 1.6× 469 0.5× 1.9k 2.2× 259 0.6× 53 4.0k
Thomas Kindler 1.5k 0.9× 1.7k 1.4× 615 0.7× 768 0.9× 118 0.3× 78 3.0k

Countries citing papers authored by Markus Warmuth

Since Specialization
Citations

This map shows the geographic impact of Markus Warmuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Warmuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Warmuth more than expected).

Fields of papers citing papers by Markus Warmuth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Warmuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Warmuth. The network helps show where Markus Warmuth may publish in the future.

Co-authorship network of co-authors of Markus Warmuth

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Warmuth. A scholar is included among the top collaborators of Markus Warmuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Warmuth. Markus Warmuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yun, Chao Quan, Xiomara Lucas, et al.. (2024). 511LBA (PB-511) LBA Posters: Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies. European Journal of Cancer. 211. 114989–114989.
2.
Rioux, Nathalie, Sherri Smith, Manav Korpal, et al.. (2018). Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). Cancer Chemotherapy and Pharmacology. 83(1). 151–160. 14 indexed citations
3.
Albacker, Lee A., Jeremy Wu, Peter Smith, et al.. (2017). Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 12(11). e0176181–e0176181. 83 indexed citations
4.
Naylor, Tara L., Huaping Tang, Boris A. Ratsch, et al.. (2011). Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas. Cancer Research. 71(7). 2643–2653. 88 indexed citations
5.
Jagani, Zainab, Dmitri Wiederschain, Alice Loo, et al.. (2010). The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells. Cancer Research. 70(13). 5528–5538. 48 indexed citations
6.
Dierks, Christine, Francisco Adrián, Paul Fisch, et al.. (2010). The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease. Cancer Research. 70(15). 6193–6204. 51 indexed citations
7.
Hassan, Amr, Sreenath V. Sharma, & Markus Warmuth. (2010). Allosteric inhibition of BCR-ABL. Cell Cycle. 9(18). 3734–3738. 23 indexed citations
8.
Stegmeier, Frank, Markus Warmuth, William R. Sellers, & Marion Dorsch. (2010). Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clinical Pharmacology & Therapeutics. 87(5). 543–552. 148 indexed citations
9.
Dierks, Christine, Katja Zirlik, Mario Stegert, et al.. (2008). Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation. Cancer Cell. 14(3). 238–249. 407 indexed citations
10.
Hur, Wooyoung, Anastasia Velentza, Sung Joon Kim, et al.. (2008). Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorganic & Medicinal Chemistry Letters. 18(22). 5916–5919. 32 indexed citations
11.
Obermeier, Axel, et al.. (2007). Role of p21WAF1/CIP1 as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Annals of Hematology. 87(3). 183–193. 15 indexed citations
12.
Galkin, Anna, Sung Joon Kim, Tami Hood, et al.. (2006). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences. 104(1). 270–275. 289 indexed citations
13.
Barun, Okram, A. S. Nagle, Francisco Adrián, et al.. (2006). A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors. Chemistry & Biology. 13(7). 779–786. 124 indexed citations
14.
Yan, S. Frank, Frederick J. King, Yingyao Zhou, Markus Warmuth, & Gang Xia. (2006). Profiling the kinome for drug discovery. Drug Discovery Today Technologies. 3(3). 269–276. 3 indexed citations
15.
Warmuth, Markus, Sung Joon Kim, Xiang-ju Gu, Gang Xia, & Francisco Adrián. (2006). Ba/F3 cells and their use in kinase drug discovery. Current Opinion in Oncology. 19(1). 55–60. 153 indexed citations
16.
Hu, Yiguo, Yuhua Liu, Elisabeth Buchdunger, et al.. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics. 36(5). 453–461. 310 indexed citations
17.
Warmuth, Markus, Robert Damoiseaux, Yi Liu, Doriano Fabbro, & Nathanael S. Gray. (2003). Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Current Pharmaceutical Design. 9(25). 2043–2059. 92 indexed citations
18.
Stanglmaier, Michael, et al.. (2003). The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia. 17(2). 283–289. 55 indexed citations
19.
Warmuth, Markus, S. Danhauser-Riedl, & Michael Hallek. (1999). Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Annals of Hematology. 78(2). 49–64. 60 indexed citations
20.
Hallek, Michael, S. Danhauser-Riedl, Ronald Herbst, et al.. (1996). Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells. British Journal of Haematology. 94(1). 5–16. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher A. Eide Breakdown of academic impact, for papers by Juerg Schwaller Breakdown of academic impact, for papers by Raajit K. Rampal Breakdown of academic impact, for papers by David R. Stover Breakdown of academic impact, for papers by Marc Loriaux Breakdown of academic impact, for papers by Shu Tamura Breakdown of academic impact, for papers by Ilaria Iacobucci Breakdown of academic impact, for papers by Hans D. Menssen Breakdown of academic impact, for papers by Thomas Mercher Breakdown of academic impact, for papers by Thomas Kindler
Rankless by CCL
2026